These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 33367629)

  • 21. Risk of All-Cause Mortality in Diabetic Patients Taking β-Blockers.
    Tsujimoto T; Kajio H; Shapiro MF; Sugiyama T
    Mayo Clin Proc; 2018 Apr; 93(4):409-418. PubMed ID: 29545006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequency of Utilization of Beta Blockers in Patients With Heart Failure and Depression and Their Effect on Mortality.
    Kim C; Duan L; Phan DQ; Lee MS
    Am J Cardiol; 2019 Sep; 124(5):746-750. PubMed ID: 31277789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the clinical outcome of different beta-blockers in heart failure patients: a retrospective nationwide cohort study.
    Bølling R; Scheller NM; Køber L; Poulsen HE; Gislason GH; Torp-Pedersen C
    Eur J Heart Fail; 2014 Jun; 16(6):678-84. PubMed ID: 24706485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of late mortality in hospitalized patients >70 years of age with systolic heart failure receiving beta blockers versus those not receiving beta blockers.
    Pascual-Figal DA; Redondo B; Caro C; Manzano S; Garrido IP; Ruipérez JA; Valdés M
    Am J Cardiol; 2008 Dec; 102(12):1711-7. PubMed ID: 19064029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beta-blocker Therapy at Discharge in Patients with Acute Heart Failure and Atrial Fibrillation.
    Ahn MS; Yoo BS; Son JW; Yu MH; Kang DR; Lee HY; Jeon ES; Kim JJ; Chae SC; Baek SH; Kang SM; Choi DJ; Kim KH; Cho MC; Kim SY
    J Korean Med Sci; 2020 Aug; 35(33):e278. PubMed ID: 32830467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decreased Mortality With Beta-Blockers in Patients With Heart Failure and Coexisting Atrial Fibrillation: An AF-CHF Substudy.
    Cadrin-Tourigny J; Shohoudi A; Roy D; Talajic M; Tadros R; Mondésert B; Dyrda K; Rivard L; Andrade JG; Macle L; Guerra PG; Thibault B; Dubuc M; Khairy P
    JACC Heart Fail; 2017 Feb; 5(2):99-106. PubMed ID: 28089316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort.
    Tang CH; Wang CC; Chen TH; Hong CY; Sue YM
    J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26738790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term prescription of beta-blocker delays the progression of heart failure with preserved ejection fraction in patients with hypertension: A retrospective observational cohort study.
    Gu J; Fan YQ; Bian L; Zhang HL; Xu ZJ; Zhang Y; Chen QZ; Yin ZF; Xie YS; Wang CQ
    Eur J Prev Cardiol; 2016 Sep; 23(13):1421-8. PubMed ID: 26915580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of guideline-consistent heart failure drug prescriptions at hospital discharge on 1-year mortality: Results from the EPICAL2 cohort study.
    Busson A; Thilly N; Laborde-Castérot H; Alla F; Messikh Z; Clerc-Urmes I; Mebazaa A; Soudant M; Agrinier N
    Eur J Intern Med; 2018 May; 51():53-60. PubMed ID: 29305071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.
    Verbrugge FH; Duchenne J; Bertrand PB; Dupont M; Tang WH; Mullens W
    Am J Cardiol; 2013 Dec; 112(12):1913-20. PubMed ID: 24286620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of medication adherence measures derived from linked administrative data and associations with mortality using restricted cubic splines in heart failure patients.
    Qin X; Hung J; Knuiman MW; Briffa TG; Teng TK; Sanfilippo FM
    Pharmacoepidemiol Drug Saf; 2020 Feb; 29(2):208-218. PubMed ID: 31958191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association Between β-Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease.
    Fu EL; Uijl A; Dekker FW; Lund LH; Savarese G; Carrero JJ
    Circ Heart Fail; 2020 Nov; 13(11):e007180. PubMed ID: 33070637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes in patients hospitalized for heart failure and chronic obstructive pulmonary disease: differences in clinical profile and treatment between 2002 and 2009.
    Staszewsky L; Cortesi L; Tettamanti M; Dal Bo GA; Fortino I; Bortolotti A; Merlino L; Latini R; Roncaglioni MC; Baviera M
    Eur J Heart Fail; 2016 Jul; 18(7):840-8. PubMed ID: 27098360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. β-Blocker use and all-cause mortality of melanoma patients: results from a population-based Dutch cohort study.
    Livingstone E; Hollestein LM; van Herk-Sukel MP; van de Poll-Franse L; Nijsten T; Schadendorf D; de Vries E
    Eur J Cancer; 2013 Dec; 49(18):3863-71. PubMed ID: 23942335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence of potential bias in a comparison of β blockers and calcium channel blockers in patients with chronic obstructive pulmonary disease and acute coronary syndrome: results of a multinational study.
    Dong YH; Alcusky M; Maio V; Liu J; Liu M; Wu LC; Chang CH; Lai MS; Gagne JJ
    BMJ Open; 2017 Mar; 7(3):e012997. PubMed ID: 28363921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial.
    Silverman DN; Plante TB; Infeld M; Callas PW; Juraschek SP; Dougherty GB; Meyer M
    JAMA Netw Open; 2019 Dec; 2(12):e1916598. PubMed ID: 31800067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program.
    Fonarow GC; Abraham WT; Albert NM; Stough WG; Gheorghiade M; Greenberg BH; O'Connor CM; Sun JL; Yancy CW; Young JB;
    J Am Coll Cardiol; 2008 Jul; 52(3):190-9. PubMed ID: 18617067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Addition of beta-blockers to digoxin is associated with improved 1- and 10-year survival of patients hospitalized due to decompensated heart failure.
    Katz A; Maor E; Leor J; Klempfner R
    Int J Cardiol; 2016 Oct; 221():198-204. PubMed ID: 27404675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The association of beta-blocker use with mortality in elderly patients with congestive heart failure and advanced chronic kidney disease.
    Molnar AO; Petrcich W; Weir MA; Garg AX; Walsh M; Sood MM
    Nephrol Dial Transplant; 2020 May; 35(5):782-789. PubMed ID: 31495887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial.
    Kitai T; Grodin JL; Mentz RJ; Hernandez AF; Butler J; Metra M; McMurray JJ; Armstrong PW; Starling RC; O'Connor CM; Swedberg K; Tang WH
    Eur J Heart Fail; 2017 Feb; 19(2):241-249. PubMed ID: 27634557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.